Skip to main content
. 2023 Jan 2;12(1):1. doi: 10.1038/s41389-022-00446-y

Fig. 5. The combination of abiraterone and AKT inhibitor MK2206 selectively and synergistically inhibited the proliferation of PCa cells in vitro.

Fig. 5

A, B PCa cell lines VCaP, CWR22Rv1, LNCaP, C4-2, or normal prostate epithelial cells RWPE-1 were seeded in 24-well plates, and then treated with stepwise concentrations of abiraterone or MK2206 for 7 days. The living cells were measured by crystal violet assay. C–G VCaP, CWR22Rv1, LNCaP, C4-2, or RWPE-1 cells were seeded in 24-well plates, and then treated with stepwise concentrations of abiraterone or MK2206 alone or in combination for 7 days. The living cells were measured by crystal violet assay. H the CI (combination index) values of abiraterone and MK2206 were calculated in PCa cells. I, J CWR22Rv1 (I), LNCaP cells (J) were treated with abiraterone or MK2206 alone or in combination for 48 h, and the apoptotic cells were stained with Annexin V/PI, and analyzed by flow cytometry. The presented results were representative of experiments repeated at least three times. Data was represented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.